Multiple trials have been terminated or withdrawn owing to unexpected complications, including the trial focused on Wilms tumor 1 (WT1) utilizing Cas9 RNP (NCT05066165) and the study of PD-1 knockout T cells in metastatic RCC (NCT02867332). Here, WT1 is linked to renal cell carcinoma.